NEWRON PHARMACEUT. EO-,20
NEWRON PHARMACEUT. EO-,20/ IT0004147952 /
NWRNZ
|
11/15/2024 6:53:43 PM
|
Chg.
-0.270
|
Volume |
Bid6:53:43 PM |
Ask6:53:43 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
7.770EUR
|
-3.36%
|
-
Turnover: - |
7.770Bid Size: - |
7.910Ask Size: - |
138.75 mill.EUR |
- |
- |
Fundamentals
| |
FY 2023 |
Growth (1Y) |
| Per Share |
|
| Earnings per Share: |
-0.91 EUR |
-7.14% |
| EPS Diluted: |
- EUR |
-7.14% |
| Revenues per Share: |
0.51 EUR |
48.62% |
| Book Value per Share: |
-1.68 EUR |
113.17% |
| Cash Flow per Share: |
-0.57 EUR |
-8.58% |
| Dividend per Share: |
- EUR |
- |
| Total |
in mill. |
|
| Revenues: |
9.06 EUR |
48.62% |
| Net Income: |
-16.22 EUR |
-7.25% |
| Operating Cash Flow: |
-10.14 EUR |
- |
| Cash and Cash Equivalents: |
6.34 EUR |
- |
Valuation Ratios
| |
Current |
Latest FY* |
| P/E Ratio: |
- |
- |
| P/S Ratio: |
15.32 |
11.03 |
| P/BV ratio: |
-4.64 |
-3.34 |
| P/CF Ratio: |
-13.68 |
-9.86 |
| PEG: |
1.20 |
- |
| Earnings Yield: |
-11.70% |
-16.25% |
| Dividend Yield: |
- |
- |
| Market Capitalization |
|
| Market Capitalization: |
138.75 mill. EUR |
99.93 mill. EUR |
| Free Float Market Cap.: |
- EUR |
- EUR |
| Market Cap. / Employee: |
- EUR |
- EUR |
| Shares Outstanding: |
17.85 mill. |
|
Profitability
| Gross Profit Margin: |
- |
| EBIT Margin: |
-128.40% |
| Net Profit Margin: |
-179.13% |
| Return on Equity: |
- |
| Return on Assets: |
-62.72% |
Financial Strength
| Liquidity I / Cash Ratio: |
21.91% |
| Liquidity II / Quick Ratio: |
46.29% |
| Liquidity III / Current Ratio: |
67.94% |
| Debt / Equity Ratio: |
- |
| Dynam. Debt / Equity Ratio: |
-550.04% |
Efficiency
| Employees: |
- |
| Personal Expenses / Employee: |
- EUR |
| Revenues / Employee: |
- EUR |
| Net Income / Employee: |
- EUR |
| Total Assets / Employee: |
- EUR |
| * Fiscal Year End: |
12/31/2023 |
| Accounting Standard: |
IFRS |
